P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Maintenance and continuous therapy for multiple myeloma
TL;DR: Results from the FIRST trial support lenalidomide plus low-dose dexamethasone (Rd) as a standard of care for continuous therapy in newly diagnosed multiple myeloma and relapsed/refractory MM, and data from additional trials are awaited.
Journal ArticleDOI
Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes
TL;DR: Adverse events observed with POM, given at 4 mg/day on days 1–21 of each 28-day cycle in combination with LoDEX, were generally comparable regardless to baseline renal function, however these data are confounded by low pt numbers.
Journal ArticleDOI
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.
Paul G. Richardson,Sagar Lonial,Andrzej Jakubowiak,Sundar Jagannath,Noopur Raje,David Avigan,Irene M. Ghobrial,Robert L. Schlossman,Amitabha Mazumder,Nikhil C. Munshi,Jacob P. Laubach,David H. Vesole,Robin Joyce,Jacalyn Rosenblatt,Wanling Xie,Deborah Doss,Diane Warren,Kate Ittleman,Carolyn Revta,Dixil Francis,Charles Leister,Sarah Kaster,Carol Delaney,Marisa Lauria,Constantine S. Mitsiades,Teru Hideshima,Robert Knight,Dixie-Lee Esseltine,Edie Weller,Kenneth C. Anderson +29 more
TL;DR: All patients had a best confirmed pre-ASCT response of 3PR, with 54% CR/nCR and 69% 3VGPR (Table).
Journal ArticleDOI
Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)
Paul G. Richardson,Andrzej Jakubowiak,Nizar J. Bahlis,David S. Siegel,Christine Chen,Min Chen,Mohamed H. Zaki,Gail Larkins,Kenneth C. Anderson +8 more
TL;DR: Efficacy outcomes and safety in pts with high-risk cytogenetic profiles were compared with those of pts with standard- risk cytogenetics as well as with the overall population who received POM+LoDEX as part of an exploratory analysis.
Journal ArticleDOI
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Sagar Lonial,Andrzej Jakubowiak,Sundar Jagannath,Marc S. Raab,Thierry Facon,Ravi Vij,Philippe Moreau,Donna E. Reece,Darrell White,Lotfi Benboubker,Jeffrey A. Zonder,Jean-François Rossi,Claire Tsao,Teresa Parli,Glenn S. Kroog,Anil K. Singhal,Paul G. Richardson +16 more
TL;DR: A Phase 1 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed/refractory MM patients demonstrated an 82% objective response rate (ORR), and the ongoing Phase 2 study to assess efficacy according to the International Myeloma Working Group criteria.